Viewpoint Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?
2009
Anti-angiogenic therapies have demonstrated their value in the setting of advanced cancer, and are being explored for use in micrometastatic disease. Recent preclinical studies suggest that adjuvant anti-vascular endothelial growth factor (VEGF) therapies may increase the risk of metastasis. How concerning are these preclinical studies, and should they affect our willingness to explore anti-VEGF therapy in the adjuvant setting?
Keywords:
- Correction
- Cite
- Save
- Machine Reading By IdeaReader
9
References
0
Citations
NaN
KQI